Omeros Corporation
Treatment of addiction and impulse-control disorders using PDE7 inhibitors
Last updated:
Abstract:
This disclosure is directed to treatment of addictions and primary impulse-control disorders using phosphodiesterase 7 (PDE7) inhibitors, alone or in combination with other therapeutic agents.
Status:
Grant
Type:
Utility
Filling date:
15 Jan 2018
Issue date:
28 Dec 2021